Study on Topotecan and Cisplatin for Ovarian Cancer
Author Information
Author(s): Gelderblom H, Sparreboom A, Jonge M J A de, Loos W J, Wilms E, Mantel M A, Hennis B, Camlett I, Verweij J, Burg M E L van der
Primary Institution: Rotterdam Cancer Institute and University Hospital Rotterdam
Hypothesis
Does the addition of Cremophor EL to a cisplatin and topotecan regimen reduce haematological toxicity in patients with recurrent ovarian cancer?
Conclusion
The study found that Cremophor EL modestly reduces haematological toxicity in a cisplatin-based regimen but does not allow for an increase in the oral topotecan dose.
Supporting Evidence
- Both weekly cisplatin and topotecan are effective in treating recurrent ovarian cancer.
- Preclinical data suggest that Cremophor EL may protect against haematological toxicity from cisplatin.
- The study involved 18 patients receiving a total of 85 courses of treatment.
Takeaway
This study looked at how a new drug combination affects patients with ovarian cancer, finding that it can help reduce some side effects.
Methodology
Phase I study with escalating doses of oral topotecan combined with weekly cisplatin and Cremophor EL.
Limitations
The study had a small sample size and focused on specific dosing schedules.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website